News | April 15, 2024
Novartis tender offer for MorphoSys commences
The offer price corresponds to a premium of 142% on the volume-weighted average price during the last three months
The offer price corresponds to a premium of 142% on the volume-weighted average price during the last three months
Aims to become a leading global partner for botanical extracts and natural actives in the beauty and personal care market
International Business is expected to register double-digit growth in constant currency terms
Combination will create a Canadian Health Champion spanning generic, biosimilar and branded pharmaceuticals
This acquisition enables MTD to open new, strategic markets
Asahi Songwon Colors' shareholding in ALSPL has increased from 78% to 100%
To accelerate the development of next-generation radioconjugates to treat cancer
Lonza plans to invest approximately CHF 500 million to upgrade the facility
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
Both organisations enter into a long- term collaboration to expand patient access in India
Subscribe To Our Newsletter & Stay Updated
